Skip to content
VectorGene
en

CHGB · Partner-reported service scope

Tumour Genetic Testing

Over 1,000 tumour-related genetic tests evaluating therapy targets per clinical guidelines, spanning targeted therapy, immunotherapy and chemotherapy selection.

Partner-reported scope
1,000+ tests
Method
NGS
Scientist pipetting into test tubes. Illustrative stock photograph.
Scientist pipetting into test tubes

CHGB · Partner-reported

Service capabilities

The following scope is reported by the partner. Quantities describe the partner portfolio and do not represent VectorGene’s own track record.

Comprehensive oncology panels
Guideline-aligned therapy target evaluation.
MSI and TMB status
HLA typing
Full genomic variation profiling

Explore the related platform.

Advanced genomic testing platforms for precision oncology, inherited disease analysis, pathogen sequencing, microbiome analysis and population-level genomic programmes.

Genomics & NGS Testing
Varies by jurisdiction

Diagnostic testing is regulated differently in every jurisdiction. VectorGene supports local validation and accreditation; the regulatory dossier remains owned by the local institution.

Explore services in this category.

Read each service’s complete scope and regulatory note. These links help you explore the portfolio; programme-specific suitability requires feasibility assessment.

Connect tumour profiling to a review pathway.

Define the tumour context, specimen availability and purpose of testing before comparing panels. A programme brief should explain how results will reach the treating team and which evidence, treatment access or trial criteria will be reviewed after a finding is reported.

Tumour biomarker testing may help identify treatment options or clinical trials. It differs from inherited-risk testing, and finding a biomarker does not guarantee that a matched treatment will work.

NCI: Biomarker Testing for Cancer Treatment

External references explain the wider context. They do not verify or endorse the supplied VectorGene or partner offering.

Questions for the programme brief

  1. Which tumour and specimen?

    Confirm tissue or blood requirements, sample adequacy review and the questions the proposed assay can address.

  2. How is clinical relevance reviewed?

    Identify who reviews variant evidence, uncertain findings and possible inherited-risk implications.

  3. What happens after a result?

    Map the clinical discussion, relevant treatment or trial access, and the reporting limitations that must accompany the result.

What to prepare for review
  • Tumour and specimen brief
  • Panel scope and example report
  • Clinical review and referral arrangements

Working environments

Sample handling and genetic analysis.

Illustrative stock photography provides context for the people, processes and working environments behind this capability.

Technician validating genetic variants in a sequencing laboratory. Illustrative stock photograph.
Technician validating genetic variants in a sequencing laboratory
Laboratory scientist preparing genetic material from a sample card. Illustrative stock photograph.
Laboratory scientist preparing genetic material from a sample card
Laboratory technician performing a barcode scan. Illustrative stock photograph.
Laboratory technician performing a barcode scan
Fluorescence microscopy of treated colorectal cancer cells. Illustrative stock photograph.
Fluorescence microscopy of treated colorectal cancer cells

Start a conversation

Discuss Tumour Genetic Testing

This service will be retained as context for your enquiry. Choose the platform or support area you want to develop at your institution.
Partner with us